Approximately 29,622 blister cards of Docusate Sodium (100mg softgels) are being recalled because the outer carton may be incorrectly labeled as Gabapentin (300mg). This labeling error means that healthcare providers or patients might accidentally administer the wrong medication, which can lead to serious health complications or leave underlying conditions untreated. The affected medication was manufactured by Aenova Holding GmBh for Rx Pak Division of McKesson Corporation and was intended for institutional use only. These products were distributed to five major distributors across the United States.
A labeling mix-up on the secondary carton poses a risk of medication error. If a patient receives Docusate Sodium instead of prescribed Gabapentin, their seizures or nerve pain may go untreated; conversely, taking Gabapentin unintentionally could cause adverse drug reactions.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.